214 related articles for article (PubMed ID: 31024166)
1. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
Mugoni V; Panella R; Cheloni G; Chen M; Pozdnyakova O; Stroopinsky D; Guarnerio J; Monteleone E; Lee JD; Mendez L; Menon AV; Aster JC; Lane AA; Stone RM; Galinsky I; Zamora JC; Lo-Coco F; Bhasin MK; Avigan D; Longo L; Clohessy JG; Pandolfi PP
Cell Res; 2019 Jun; 29(6):446-459. PubMed ID: 31024166
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
[TBL] [Abstract][Full Text] [Related]
3. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
[TBL] [Abstract][Full Text] [Related]
7. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
8. Effects of different autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy.
Haghi A; Salemi M; Fakhimahmadi A; Mohammadi Kian M; Yousefi H; Rahmati M; Mohammadi S; Ghavamzadeh A; Moosavi MA; Nikbakht M
IUBMB Life; 2021 Jan; 73(1):130-145. PubMed ID: 33205598
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Valenzuela M; Glorieux C; Stockis J; Sid B; Sandoval JM; Felipe KB; Kviecinski MR; Verrax J; Buc Calderon P
Br J Cancer; 2014 Aug; 111(5):874-82. PubMed ID: 25003661
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
[TBL] [Abstract][Full Text] [Related]
11. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
12. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
13. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
[TBL] [Abstract][Full Text] [Related]
14. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
15. Unlocking the potential of retinoic acid in anticancer therapy.
Schenk T; Stengel S; Zelent A
Br J Cancer; 2014 Nov; 111(11):2039-45. PubMed ID: 25412233
[TBL] [Abstract][Full Text] [Related]
16. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
17. [State-of-the-art treatment of acute promyelocytic leukemia].
Kiguchi T
Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
[TBL] [Abstract][Full Text] [Related]
18. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
[TBL] [Abstract][Full Text] [Related]
20. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]